The use of ciclosporin in psoriasis: A clinical review

British Journal of Dermatology, Supplement

Volumn 150, Issue 67, 2004, Pages 1-10

  Ho, V C ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Ciclosporin; Intermittent short course therapy; Psoriasis

Indexed keywords

CYCLOSPORIN; ETRETINATE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RETINOID;

BLOOD PRESSURE; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GINGIVA HYPERPLASIA; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LONG TERM CARE; META ANALYSIS; NAUSEA; NEPHROTOXICITY; PARESTHESIA; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PUVA; QUALITY OF LIFE; SIDE EFFECT; SKIN CANCER; STATISTICAL SIGNIFICANCE; ULTRAVIOLET B RADIATION;

EID: 3142622737     PISSN: 0366077X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0366-077x.2004.05950.x     Document Type: Conference Paper

References (39)

1. Griffiths CEM, Clark CM, Chalmers RJG, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000: 4: 40.
2. Finlay AY, Khan GK, Luscombe D, Salek MS. Validation of the Sickness Impact Profile and Psoriasis Disability Index in psoriasis. Br J Dermatol 1990; 123: 751-6.
3. Fredriksson T, Petterson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
4. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CEM. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis specific stress. Br J Dermatol 1997; 137: 755-60.
5. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CEM. Patients with psoriasis and their compliance with medication. J Am Acad Derm 1999; 41: 581-3.
6. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197 (1): 31-6.
7. Mrowietz U, Ruzicka T. Cyclosporin A for psoriasis. Dermatologic Ther 1999; 11: 60-6.
8. Gordon KB, Koo JYM, Feldman SR, Menter A, Krueger G. Definitions of measures of effect duration for psoriasis treatments. National Psoriasis Foundation Professional Member Newsletter 2002; 8: 1-3.
9. Finlay AY, Coles EC. The effect of psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-44.
10. Gupta MA, Gupta AK. The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress. Acta Derm Venereol (Stockh) 1995; 75: 240-3.
11. Finlay AY, Kelly S. Psoriasis - an index of disability. Clin Exp Dermatol 1987; 12: 8-11.
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6.
13. Ware JE, Sherbourne CD. The MOS 36-item Short Form Health Survey (SF-36): 1: conceptual framework and item selection. Med Care 1992; 30: 473-83.
14. Berth-Jones J, Henderson CA, Munro CS et al. Treatment of psoriasis with intermittent short-course cyclosporin (Neoral®). A multicentre study. Br J Dermatol 1997; 136: 527-30.
15. Ho VCY, Albrecht G, Vanaclocha F et al. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomised study. Br J Dermatol 1999; 141: 283-91.
16. Ho VCY, Griffiths CEM, Berth-Jones J et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44: 643-51.
17. Faerber L, Braeutigam M, Weidinger G et al. Cyclosporine in severe psoriasis: Results of a meta-analysis. Am J Clin Dermatol 2001; 2: 41-7.
18. Touw CR, Hakkaart-Van Roijen L, Paul C, Rutten EFH, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001; 144: 967-72.
19. Heydendael VMR, Spuls PI, Opmeer BC et al. Effectiveness, safety and quality of life of methotrexate versus cyclosporin A in moderate to severe psoriasis: a randomised controlled trial. Br J Dermatol 2002; 147: 1058 (Abstract 21).
20. Powles AV, Baker BS, Valdimarsson H, Hulme B, Fry L. Four years of experience with cyclosporin A for psoriasis. Br J Dermatol 1990; 36 (Suppl.): 13-9.
21. Christophers E, Mrowietz U, Henneicke H, Faerber L, Welzel D. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. J Am Acad Dermatol 1992; 26: 86-90.
22. Mrowietz U, Faerber L, Henneicke-von Zepelin HH, Bachmann H, Welzel D, Christophers E. Long-term maintenance therapy with cyclosporine and post-treatment survey in severe psoriasis, results of a multicenter study. J Am Acad Dermatol 1995; 33: 470-5.
23. Shupack J, Abel E, Bauer E et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997: 36: 423-32.
24. Koo J, OLP302 Study Group. A randomised, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin. Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol 1998; 139: 88-95.
25. Vanaclocha F, Puig L, Daudén E et al. Effectiveness of cyclosporine in patients with psoriasis. 9th International Psoriasis Symposium, New York, June 17-22, 2003.
26. Puig L, Vanaclocha F, Daudén E et al. Quality of life in psoriatic patients treated with cyclosporine. 9th International Psoriasis Symposium, New York, June 17-22, 2003.
27. Clark CM, Kirby B, Morris AD et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Dermatol 1999; 141: 279-82.
28. Mihatsch MJ, Belghiti D, Bohman SO et al. Kidney biopsies in control or cyclosporin A treated psoriatic patients. Br J Dermatol 1990; 122: 95-100.
29. Mihatsch MJ, Wolff K. A consensus report: Cyclosporin A therapy for psoriasis. Br J Dermatol 1990; 122 (Suppl. 26): 1-3.
30. Daudén E, Vanaclocha F, Puig L et al. Safety of cyclosporine in patients with psoriasis. 9th International Psoriasis Symposium, New York, June 17-22, 2003.
31. Markham T, Watson A, Rogers S. Adverse effects with long-term cyclosporin for severe psoriasis. Clin Exp Dermatol 2002; 27: 111-4.
32. Lowe NJ, Wieder JM, Rosenbach A et al. Long-term low-dose cyclosporine therapy for severe psoriasis: effects on renal function and structure. J Am Acad Dermatol 1997; 37 (4): 671-2.
33. Feutren G, Abeywickrama K, Friend D et al. Renal function and blood pressure in psoriatic patients treated with cyclosporin A. Br J Dermatol 1990; 122 (Suppl. 36): 57-9.
34. Feutren G, Mihatsch MJ. Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporin in Autoimmune Diseases. N Engl J Med 1992; 326: 1654-60.
35. Powles AV, Cook T, Hulme B et al. Renal function and biopsy findings after 5 years treatment with low-dose cyclosporin for psoriasis. Br J Dermatol 1992; 128: 159-65.
36. Pei Y, Scholey JW, Katz A et al. Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine. Am J Kid Dis 1994; 23: 527-36.
37. Young EW, Ellis CN, Messana JM et al. A prospective study of renal structure and function in patients treated with cyclosporin. Kidney Internat 1994; 46: 1216-22.
38. Paul C, Ho VC, McGeown C et al. Risk of malignancies in psoriasis treated with cyclosporine: a 5-yr cohort study. J Invest Dermatol 2003; 120: 211-6.
39. Griffiths CEM, Dubertret L, Ellis C et al. Ciclosporin in clinical practice: an international consensus statement. Br J Dermatol 2004; 150: 11-23.